Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

25.72
-0.1100-0.43%
Post-market: 25.720.00000.00%16:15 EDT
Volume:1.53M
Turnover:39.46M
Market Cap:2.53B
PE:-4.41
High:26.09
Open:25.75
Low:25.30
Close:25.83
52wk High:39.89
52wk Low:18.29
Shares:98.32M
Float Shares:94.49M
Volume Ratio:0.63
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-8.69
PE(LYR):-4.41

Loading ...

Ultragenyx says FDA accepts UX111 gene therapy BLA resubmission, sets Sept. 19 PDUFA date

Reuters
·
Apr 02

Ultragenyx Pharmaceutical Inc - FDA Sets Pdufa Action Date for Ux111 on September 19, 2026

THOMSON REUTERS
·
Apr 02

Ultragenyx Announces U.S. FDA Acceptance of Bla Resubmission for Ux111 Aav Gene Therapy to Treat Sanfilippo Syndrome Type a (Mps Iiia)

THOMSON REUTERS
·
Apr 02

Ultragenyx Pharmaceutical Inc - Ux111 to Be Manufactured in U.S. at Andelyn Biosciences and Ultragenyx Facility IF Approved

THOMSON REUTERS
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Mar 30

Ultragenyx announces FDA clearance of UX016 investigational new drug application

TIPRANKS
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Mar 30

BUZZ-Ultragenyx rises after FDA clears human trial for rare muscle disease drug

Reuters
·
Mar 30

Ultragenyx wins FDA IND clearance for UX016 in GNE myopathy

Reuters
·
Mar 30

Ultragenyx Pharmaceutical Inc - Phase 1/2 Study of Ux016 Expected to Begin in H2 2026

THOMSON REUTERS
·
Mar 30

Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After Its Prolonged Share Price Slump?

Simply Wall St.
·
Mar 29

Ultragenyx announces annual stockholders meeting; FY2025 revenue grows 20%

Reuters
·
Mar 28

BROAD ARROW PRESENTS RARE OPPORTUNITY TO ACQUIRE FERRARI MONZA SP2 AT CONCORSO D’ELEGANZA VILLA D’ESTE AUCTION

GlobeNewswire
·
Mar 27

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Mar 25

Why Ultragenyx (RARE) Is Down 14.4% After Positive Phase 3 DTX301 Gene Therapy Results

Simply Wall St.
·
Mar 25

Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral From Buy, Adjusts PT to $25 From $61

MT Newswires Live
·
Mar 24

Ultragenyx downgraded to Neutral from Buy at Goldman Sachs

TIPRANKS
·
Mar 24

Ultragenyx grants 10,839 restricted stock units under employment inducement plan

Reuters
·
Mar 21

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 21

Analysts Conflicted on These Healthcare Names: Immutep (IMMP) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Mar 15